References
[1] H. L, Ym W, Jy X, et al. [Potential antiviral therapeutics for 2019 novel coronavirus]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tubercul Respir Dis, 43 (2020), p. E2
[2] Mahase Elisabeth. Covid-19: Remdesivir is helpful but not a wonder drug, say researchers BMJ 2020; 369 :m1798
[3] Jan H, Faisal S, Khan A, et al. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries (Craiova). 2020;8(2):e108. Published 2020 Apr 26. doi:10.15190/d.2020.5
[4] Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19 [published online ahead of print, 2020 Mar 5]. Travel Med Infect Dis. 2020;101615. doi:10.1016/j.tmaid.2020.101615
[5] Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653. doi:10.1126/scitranslmed.aal3653
[6] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269‐271. doi:10.1038/s41422-020-0282-0
[7] Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. Published 2020 Jan 10. doi:10.1038/s41467-019-13940-6
[8] Richard TE, Jacob SR, Kyle RB, et al. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Central Science Article ASAP DOI: 10.1021/acscentsci.0c00489
[9] M.L. Holshue, C. DeBolt, S. Lindquist, K.H. Lofy, J. Wiesman, H. Bruce, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med, 382 (10) (2020), pp. 929-936 - showed good response to remdisivir
[10] Kujawski, S. A., Wong KK, Collins JP et al. First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. MedRxiv, 2020, DOI: 10.1101/2020.03.09.20032896
[11] Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007016.
[12] Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe covid-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2020.www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext .
[13] ClinicalTrials.gov. Adaptive COVID-19 Treatment Trial (ACTT).https://clinicaltrials.gov/ct2/show/NCT04280705 .
[14] NIAID News Release, April 29, 2020. NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19. (https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19)
[15] FDA News Release, May 1, 2020. Remdesivir EUA Letter of Authorization. (https://www.fda.gov/media/137564/download )
[16] WHO. “Solidarity” clinical trial for COVID-19 treatments.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments .